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Control serum levels of IL-6 measured by ELISA in 
30 healthy blood donors or volunteers were 18±34 
pglml (mean ± sm. Pretransplant serum levels of IL-6 
in 169 adult candidates for liver transplantation were 
significantly higher than control in those with fulmi-
nant hepatitis (203:232 pglml) , alcoholic cirrhosis 
(116:257 pglml), and hepatocellular carcinoma (82: 
105 pglmD. With these data as background, plasma or 
serum levels of IL-6 were monitored in 24 adult pa-
tients after first OLT and correlated with the clinical 
courses and the histopathological diagnosis of rejec-
tion. Serum or plasma levels of IL-6 decreased after 
transplantation regardless of pretransplant value. 
Four patients with infection subsequently developed 
continuously high IL-6 values. In the 20 of 24 patients 
who did not have infection, significantly higher levels 
of IL-6 were consistently found 0-4 days before his-
topathological diagnosis of rejection (131±78 pglml) 
compared with significantly lower values in patients 
without rejection episodes (40:21 pglmD. The eleva-
tions of IL-6 were spike shaped, did not correlate well 
with the histopathological grades of rejection. and 
were highly responsive to augmented immunosup-
pression. These 20 cases were classified as: group I, no 
spikes of IL-6 after liver transplantation; group 2, 
single spike of IL-6 after liver transplantation; and 
group 3, multiple spikes of IL-6 after liver transplan-
tation. The combined early and late graft loss of each 
group was 0% (group 1),25% (group 2', and 67t:"c (group 
3). We conclude that daily monitored serum or plasma 
IL-6 levels can be a good premonitor of liver allograft 
rejection and also a useful predictor of long-term graft 
outcome. 
The diagnosis of liver allograft rejection is based largely on 
liver function tests. Although they can assess the graft dam-
age associated with rejection, histopathological findings have 
been the gold standard. Markers of immune activation and 
mediators of inflammation, such as IL-2, soluble IL-2R 
I sIL-2R l. * and TNF -a could provide noninvasive methods of 
diagnosis of rejection, IL·6 is an immunoregulator of cell 
growth and differentiation that is produced mainly by human 
monocytes/macrophages, fibroblasts, endothelial cells. and 
activated T cells ( 1 !. IL-6 is one of the principal mediators of 
intlammation (2) and an inducer of the hepatic svnthesis of 
the maJonty of acute phase proteins (3, .J J. Because the liver 
is a major target organ for IL-6 (5)' and because allograft 
rejection is fundamentally an inflammatory response. we 
prospectlvelv studIed the relationship of serum or plasma 
IL-6 after liver transplantation and liver allograft rejection. 
MATERIALS AND METHODS 
Healthy volunteers, IL-6 was measured in 30 randomly selected 
blood donors and healthy laboratory personnel. 
Liver transplant candidates. Preoperative IL-6 was measured in 
169 consecutive infection-free candidates for first OLT or abdominal 
organ cluster transplantation between March 1988 and November 
1990 at the Presbyterian-University Hospital of Pittsburgh, Univer· 
sity of Pittsburgh, Pittsburgh, PA. The age, sex. and original disease 
distribution are listed in Table 1. 
Liver transplant recipients. Twenty-four adult patients (15 males 
and 9 females, mean age 49.3 years, range 28-64 years) who actually 
underwent first OLT were selected randomly for pre· and postopera-
tive IL-6 studies between November 1989 and March 1990. The 
indications for OLT were chronic active hepatitis in 3, cirrhosis in 19, 
and malignancy in 2 (Table 2). The mean follow-up for IL·6 meas-
urement was 26 days (range 13-48 days), 
Immunosuppression. Baseline immunosuppression was with 
FK506 (n=22' or CsA(n=2l. to which variable doses ofmethylpred-
nisolone were added; OKT3 was given when indicated. One CsA-
treated patient was SWitched to FK506 because of CsA-resistant 
rejection. 
Diagnosis and treatment of rejection. Episodes of rejection sus· 
pected on clinical grounds were confirmed by histopathological find-
ings of biopsy specimens. Grading of acute cellular rejection was by 
one of us (A.J.D.,.lnitial treatment of rejection was with intravenous 
methylprednisolone (steroid bolus). Patients failing to respond were 
given high·dose steroid recycle over 5 days, or OKT3 was instituted. 
Samples. Blood samples were separated to serum (all candidates, 
169 samples: 8 OLT reCipients. 123 samples 1 or plasma t 16 OLT 
recipients. 284 samples I. The blood samples were maintained at 4°C 
during preparation. and the serum or plasma stored at -20°C. The 
postoperative samples were collected daily. except on weekends. In 
patients suspected of reJl'ction. samples were aiways taken on the 
day of biopsy, and the :2 succeeding days. In most of these cases, 
samples were available for the preceding 4 days. 
IL·6 Assa.v. ELISA was performed by two-step sandwich enzyme 
Immunoassay method usmg a commerCially available ELISA kit 
IQuantikine human IL-6 immunoassay, Research and Diagnostic 
SYstems. Inc .. Minneapolis. MN). according to the manufacturer's 
i~structionsK Briefly, 50 III of assay butTer t buffered protem base) 
were added to 96-well microplates coated with mouse anti-human 
I L·6 mAb t first antibody I. Then. 200 III of test samples were added to 
mIcroplates. After :.I-hr incubation at room temperature. the wells 
were washed, 200 Ill. of horseradish peroxidase-conjugated goat anti· 
human lL-6 polyclonal antibodv were added. and incubation was 
earned out at room temperature tor :.I hr. The wells were washed as 
above and incubated at room temperature jt)r 20 mm With chromo· 
~enK which was a mixture of HeO, and tetramethvlbenzidine. After a 
last incubation. 50 III of O~ H.$O, were added to stop the reaction 
:lnd optical density at ~RM nm was measured using a microtlter 
n'ader tTitertek Multiskan. Flow Laboratones. Inc .. McClean. VAl. 
The standard curve for IL-6 ran~ng from a1.3 pgJml to 2000 pgtml 
was drawn bv logllog scale. IL-6 values of the samples were calcu-
I Address corresponcience to: Dr. T. Starz!. Department of Surgery. lated bv thIS 'standard curve. Assav sensitivity was 10 pglm!. 
l.'niversltv of Pittsbureh. 3601 Fifth Avenue. Pittsburgh. PA 15213. Stat;stlcai analvsls. Difference In lL-6 levels between each candl-
. ,\bbrevlatlOns: POD. postoperative day; slL-2R. soluble IL-:.IR. date group were analyzed by t-itudent"s t tests. Serum and plasma 
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TABLE 1. Profiles and pretransplant serum levels of IL-6 in liver transplant candidates In = 169) with various end-stage 
liver diseases 
Serum levels of IL-6 
Category Disease" Sex Age n (M:F) Mean (Range) Mean ~ SD >86 pg/ml 
I pglml) (%) 
Hepatitis Chronic active hepatitis 13 7:6 46.2 El~4F 17:::25 0 
Fulminant hepatitis 21 9:12 36.0 (15-63) 203:::232 50 
Cirrhosis PNC due to autoimmune hepatitis 14 1:13 36.1 (16-64) 4:::10 0 
PNC due to viral hepatitis 19 15:4 43.0 (19-67) 0:::0 0 
Primary biliary cirrhosis 25 2:23 54.7 (41-66) 9:::17 0 
PSC with UC or Crohn 11 11:0 43.8 (29-61) 8:::15 0 
PSC without UC or Crohn 23 14:9 41.609-66) 3:::6 0 
Alcoholic 21 18:3 45.5 (25-64) 116:::257 24 
Malignancy HeptocelluIar carcinoma 12 10:2 52.4 (21-63) 82:::105 33 
Other liver malignancyb 10 3:7 42.4 (29-58) 2:::5 0 
• Abbreviations used in table: PNC, postnecrotic cirrhosis; PSC, primary sclerosing cholangitis; UC, ulcerative colitis; Crohn, Crohn's 
disease. 
; Other liver malignancy: cholangiocelluIar carcinoma (n = 4), epitheloid hemangioendothelioma (3), carcinoma of papilla Vater (1), colon 
carCInoma liver metastasis (1), leiomyosarcoma of stomach liver metastasis (1). 
TABLE 2. Profiles of liver transplant recipients who underwent first liver transplantation In = 24) 
Category 
Hepatitis 
Cirrhosis 
~talignancy 
Disease 
Chronic active hepatitis 
PNC due to autoimmune hepatitis 
PNC due to viral hepatitis 
Alcoholic 
SBC· due to biliarY atresia 
Hepatocell ular car~inoma b 
n 
3 
1 
7 
10 
1 
2 
Sex Age 
IM:F) Mean (Rangel 
1:2 40.3 (28-59) 
1:0 58 (58) 
3:4 44.1 (33-61) 
7:3 50.3 (37-64) 
1:0 34 (34) 
2:0 57.5 (51-64) 
• Abbreviations used in table: PNC. postnecrotic cirrhosis: SBC. secondary biliary cirrhosis. 
; Hepatocellular carcinoma; hepatocellular carcinoma with PNC due to viral hepatitis (n = 1), hepatocellular carcinoma with alcoholic 
cirrhosis (n 
peak levels of IL-6 after OLT were determined as mean ::: SD. A 
P-value of less than 0.01 was considered significant. 
RESULTS 
Health.v volunteers. The nonnal mean value ofIL-6 from 30 
healthy volunteers was 1U~P4 pglml (range 0-158 pglmll. 
1Wenty-one (70%) had nondetectable« 10 pglmO levels. We 
defined the normal IL-6 cutoff level as 86 pglml, which was 
the mean::: 2S0 value of the 30 healthy volunteers. Two (7'1:) 
of the 30 had lL-6 levels greater than 86 pglml. 
Correlation between serum and plasma leL'els of IL-6. A 
high degree of correlation was found between serum and 
plasma levels of lL-6 from 10 same blood samples (r=0.991). 
Serum levels 01" IL-6 in 169 liver transplant candidates. 
Elevated serum levels greater than the cutoff value of 86 
pglml were observed in the patients with fulminant hepatitis 
150'7r: mean :203:::232 pglmil alcoholic cirrhosis (24%: mean 
116 ~ORT pg/ml). and hepatocellular carcinoma 133%: mean 
IDi~::: 105 pglmll. Candidates With other diseases had IL-6 
within the :.2 SO range I Table 1). 
IL-6 mOnitoring ol24 liver transplant reciplents. The 24 
patients studied postoperatively had a total of 28 liver trans-
plants: J reqUired retransplantatlOn because of primary non-
function In =:2) or rejection (n = 11 and 1 required a third 
transplantatIOn because of persistent rejection. The shortest 
hospital course was 13 days and the longest course was 8 
months. The latter patient died of sepsis and multiple svs-
terns organ failure. A total of 407 (123 serum and 284 plasma, 
~amples were analyzed for IL-6 concentration over the aver-
age monitoring period of 26 days (range 13-48 days). In the 
patients without infection and with stable well-functioning 
grafts, serum or plasma lL-6 levels remained within normal 
range no matter what the pretransplant values (Fig. 1). Four 
patients suffering from bacterial infection had persistently 
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FIGURE 1. Serum IL-6 before and after tirst liver transplantatIOn In 
24 recipients. 
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FIGURE 2. Serum or plasma IL-6 mOnItoring in 4 representative liver transplant recipients. Arrows shows the time of biopsy or drug 
adminIstratIOn. (A) Group 1: case EM. alcoholic cirrhosis and hepatocellular carcinoma. 64-year-old man: (8) group 2: case EF. cryptogenIc 
cirrhosIs. 61-year-old woman: Ie) group 3: case DM. cryptogenic cirrhosis. 48-year-old man: ID) group 4: case TM. postnecrotlc cirrhosis due 
to hepatitis B. 56-year-old man. 
increased IL-6 levels during these episodes to as high as or 
higher than 1000 pgJml. 
With acute cellular rejection in the 20 uninfected patients. 
IL-6 was increased from 0 to 4 days before the histopatho-
logical diagnosis of rejection. These elevations occurred in 
sPlkes. and always fell rapidly Wlthin 48 hr after the insti-
tution of antirejection therapy whether this was successful or 
not. However. when rejection was not controlled or recurred. 
IL-6levels increased again. A total of29 biopsles were done in 
these 20 reCIpients during the IL-6 momtoring penod. 
Twenty-one of the biopsles had unequivocal eVidence of acute 
cellular rejection. whereas 8 had equivocal or no evidence of 
reJectIOn. With a histopathological diagnosis of rejection. the 
mean peak values of IL-6 levels were 131:!: 78. and without 
this diagnosis the values were 40:::21 (P<O.Oll. A mean peak 
value of serum IL-6 levels was weater than ti6 pgJml in 76th-
of the rejection group and Ot} in the nonreJection group 
( P<O.Oll. 
In the uninfected patients with acute cellular rejection. 
there was not a clear correlation between IL-6 peak values 
and histopathological grades of rejection. nor was there a 
correlation between IL-6 levels and white blood cell count. 
total bilirubin. serum glutamic oxaloacetic transaminase. se-
rum glutamic pyruvic transaminase. alkaline phosphatase. 
and "y-GTP levels. Rather. the correlation appeared to be be-
tween the outcome and number ofIL-6 spikes (Table 3), How-
ever. when these 20 patients were classified according to the 
numbers of IL-6 spikes as group 1 (no spike). group 2 (single 
spike). and (3) woup 3 (multiple spikes). those of group 3 
,.;utfered severer histopathological reJectIOn and a higher 
mortality. 
IL-6 levels from 4 representative patients (3 uninfected 
and 1 infected) are plotted in Figure :2. Fih>'Ure 2A shows a 
normal IL-6 protile of a patlent who had an uneventful post-
operative course. The patient in Figure :2B had a moderate 
rejection with an IL-6 spIke on the sixth postoperative day 
(POOl. a biopsy shOWIng rejection on POD 7. and successful 
treatment with sterOIds on POD 8. 
The course in Figure :lC is from a patient with early isch-
emic injury and later severe acute cellular rejection. Postop-
1 
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eratively, IL-6 levels were low on POD 5, at which time the 
biopsy showed ischemic damage. The markedly increased 
early postoperative bilirubin levels gradually fell until the 
diagnosis of mild acute cellular rejection was made on POD 
21. Two days before this diagnosis. IL-6 levels increased 
slightly. Eight days later. severe acute cellular rejection was 
diagnosed by biopsy, at which time there was an IL-6 spike 
that resolved with OKT3 treatment. Figure 2D shows the 
IL-6 values of a patient with necrotizing fasciitis and abdomi-
nal abscesses from the second postoperative week. IL-6 levels 
rose steadily to astronomical levels. 
DISCUSSION 
Recently, measurements of plasma. serum, urine, or bile 
cytokine levels have been reported as indicators of the early 
diagnosis of rejection. Products of activated T lymphocytes. 
such as IL-2 or soluble components of its receptor (sIL-2Rl. 
have been particularly well studied. Perkins et a1. (6) and 
Adams et al. (7) reported the efficacy of sIL-2R in serum and 
bile as an indicator of liver allograft rejection. but these mea-
sures have not been widely applied. The monocyte/macro-
phage-derived cytokines, TNF-a, and IL-6 are released in 
relatively large amounts early in the immune activation pro-
cess and can be detected readily in the circulation by a sen-
sitive ELISA assay. Imagawa et al. (8) described elevated 
serum TNF-a values as predictive of human liver allograft 
rejection and, in rats, Tono et al. (9) observed that bile IL-6 
levels correlated with the severity of rejection. Van Oers et al. 
( 10) and Yoshimura et a1. ( 11 ) reported the efficacy of IL-6 for 
diagnosing renal allograft rejection. 
In our study, it was observed that the pretransplant IL-6 
value depended upon the nature of the original liver disease. 
Preoperative elevations were common with fulminant he-
patic failure. alcoholic cirrhosis, and neoplastic disease. In 
fulminant hepatIC failure. or with end-stage chronic failure. 
sepsis and endotoxemia and/or impairment of liver reticu-
loendothelial system function are common (121. This reticu-
loendothelial system function impairment allows a variety of 
gut-derived antigens to be released into the general circula-
tion. presumably \V1th IL-6 production. Muto et al. (] 3) re-
ported that TNF-a production was increased and correlated 
closely with activity of IL-l. IL-6 is also a monokine produced 
by monocytesimacrophages in response to infection and endo-
toxin. Alcohol increases the permeability of gastrointestinal 
mucosa. and could result in increased absorption of macro-
molecules. such as dietary or bacterial proteins, into the gen-
eral circulation. Alcohol also impairs Kupffer cell phagocytic 
function. theoretically predisposing to excessive production 
of IL-6 with alcoholic cirrhosis. Deviere et al. (J4, 15) have 
reported increased serum levels of IL-6 and in vitro sponta-
neous or induced excessive production of IL-6 by PBMe of 
alcoholic cirrhosis patients. 
In patients with hepatocellular carcinoma. elevated serum 
IL-6 levels also have been reported, which is not surprising 
because IL-6 is a common participant in the host-tumor in-
teraction (J6). Increased erythrocyte sedimentation rate, in-
creased serum levels of acute phase proteins, decrease in 
serum albumin, and fever are common systemic features in 
tumor-bearing hosts. These features are strongly associated 
with the function of IL-6. Tabibzadeh et al. (17) reported the 
distribution of IL-6 immunoreactivity in different human tu-
mors using an immunohistochemical technique, leaving un-
resolved the question of whether neoplastic cells secrete IL-6 
or merely accumulate it. However. elevated IL-6 levels in 
circulation have been observed in patients with neoplastic 
diseases US), and Matsuguchi et a!. (]9) observed production 
of IL-6 from human liver cell lines. 
No matter what the pretransplant value. our studies sug-
gest that IL-6 levels in the absence of infection are initially 
normalized with successful o LT. These observations are po-
tentially at variance with those of Fugger et al. (20), who 
reported that intraoperative endotoxin. TNF-a, and IL-6 
were closely (and presumably causally) related to postopera-
tive rejection and infection; such an association of preopera-
tive endotoxin and postoperative morbidity also has been 
reported in our earlier cases by Yokoyama et a1. (12) and 
Miyata et al. (21). The normalization in our patients was 
interrupted by rejection. 
Rejecting liver allografts are characterized by a cellular 
infiltration consisting mainly of monocyteslmacrophages and 
T lymphocytes, all of which may secrete IL-6. In addition. 
liver Kupffer cells and vascular endothelial cells also secrete 
IL-6. Therefore. infiltrating host immune cells or cells of the 
allograft could have a role in producing IL-6. In addition. the 
liver is the major target organ of IL-6 (.5). In a counterregu-
latory process. IL-6 stimulates pituitarY cells to release ad-
renocorticotrophic hormone and subsequently result in the 
synthesis of corticosteroids (221. The systemic glucocortico-
steroids inhibit production of IL-6. The data herein reported 
have suggested a possibility of IL-6 regulation by steroid 
TABLE 3. Relation of serum or plasma fL-6 levels to histopathological diagnosis of rejection and eventual mortality in liver 
transplant recIpients In = ~4F 
Group n Pathologlcsl d'SI(TlO818 ~fortKalily 
No ACRo -I 
:-';0 IL·6 spIke 6 ~finimal-mild ACR :! 0/6 (0%) 
'h'TOUP 1 J ~foderate·severe ACR 0 
:-':oACR :J 
Single fL·6 SPIke fl ~finimal-mild ACR 1 :VS (25%) 
'hrroup ZJ ~loderate-severe ACR -I 
NoACR 0 
~lultlple lL-6 spIkes 6 ~linimal·mtld ACR 1 ,1/6 (67%) 
'group 3) ~foderate-severe ACR ;) 
NoACR " 
Continuously high IL-6 -I Minimal-mUd ACR " V4 (100%) 
'h'TOUp 4) ~loderate-severe ACR tJ 
. ACR. acute cellular rejection • 
r 
! 
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treatment inasmuch as lL-6 levels fell within 48 hr of bolus 
steroid therapy, whether or not rejection was brought under 
control. 
The direct influence of other immunosuppressive drugs on 
IL-6 can only be speculated upon. CsA and FK506 are 
thought not to inhibit IL-6 production in vitro (23). Anti-CD3 
murine mAb (OKT3) actually raises IL-6levels in transplant 
recipients (24, 25). However, in our study, even in the patient 
treated with GKT3, we could not observe an increase of IL-6. 
IL-6 spikes always appeared at the time of first rejection 
episode, or with recurrence of rejection. These observations 
suggest that the rejection (or alternatively infection), rather 
than the drugs used for treatment, was the dominant factor 
in the determination of IL-6 levels. 
In clinical application, the IL-6 rises due to rejection, 
whereas increases caused by infection appear to be distin-
guishable. With bacterial infection, serum IL-6 levels were 
unrelentingly elevated, usually to extraordinary heights 
(> 1000 pglmll. This pattern contrasted with the spikes of 
IL-6 seen with rejection that were quickly responsive to in-
tensification of immunosuppression. The need for serial test-
ing can be met with current technology. The IL-6 ELISA 
assay takes less than 5 hr. 
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